Business
Stem Cell Therapy
Organoid
Stem Cell and CDMO Business
R&D
Core Technology
Press Release
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
Kangstem Biotech completes phase 2a clinical trial of 'OSCA', a treatment for knee osteoarthritis
10
2025.11
- "Early completed dosing with high expectations... Clinical speed, data all positive"
Kangstem Biotech announced on the 10th that it has completed dosing for all 113 patients in its Phase 2a clinical trial of ‘OSCA’, the company’s knee osteoarthritis treatment candidate. OSCA is a new investigational drug being developed as the world’s first fundamental treatment for knee osteoarthritis, designed to restore the structural integrity of cartilage and subchondral bone.
The Phase 2a trial divides participants into medium-dose, high-dose, and placebo groups to evaluate safety and efficacy compared to placebo. In the Phase 1 study, MRI analyses confirmed improvements in cartilage and subchondral bone structure, and a single administration demonstrated pain relief and functional improvement lasting over one year. The company explained that the trust built among clinical investigators due to these promising results contributed to the early completion of patient dosing in Phase 2a.
Bae Yo-Han, Head of Clinical Development at Kangstem Biotech, stated,
“Thanks to the rapid pain reduction and improvement in joint function observed in Phase 1, patient recruitment progressed very quickly. The long-term follow-up data, extending beyond one year after dosing, continue to show positive outcomes. Based on internal simulations, we also expect the Phase 2a trial to achieve strong statistical significance.”
He added,
“We are in ongoing discussions with multiple pharmaceutical companies in the U.S., Europe, and China regarding technical transfer. Since this trial was designed to reflect the requirements of these partners—such as patient numbers and placebo-controlled evaluation—they are closely watching the top-line results of OSCA’s clinical trial.”
Given the early completion of dosing, the company expects top-line results from the Phase 2a trial to be available ahead of schedule. Kangstem Biotech plans to complete final patient observation in Q2 2026 and announce top-line data in Q3 2026. Based on these results, the company intends to hold a Pre-IND meeting with the U.S. FDA to prepare for U.S. clinical trials and finalize overseas licensing deals to achieve global technical transfer.
A company representative commented,
“OSCA is an innovative new drug aimed not merely at symptom relief but at fundamental disease modification through cartilage regeneration. With the simultaneous acceleration of clinical progress and licensing discussions, next year will mark the first year of Kangstem Biotech’s global expansion.”
As the world faces an aging population, the global osteoarthritis patient population is estimated at around 600 million, and the treatment market continues to grow rapidly. According to recent market research, the global osteoarthritis therapeutics market is valued at USD 8.5 billion in 2024, and is expected to grow at a compound annual rate of 7–8%, reaching USD 24 billion by 2034.
For more details, Please refer to the link below
https://www.yakup.com/news/index.html?mode=view&cat=12&nid=318598
#kangstembiotech #stemcell #cell #stemcelltherapy #celltreatment #osteoarthritis #OSCA